Partners Acadia Pharmaceuticals Inc. and Neuren Pharmaceuticals Ltd. have unveiled positive Phase II data for pediatric Rett syndrome patients that puts their molecule, trofinetide, on track for launch of a Phase III study later this year.
Acadia, Neuren Headed To Phase III With Trofinetide In Rett Syndrome
Positive Phase II data in the unmet medical need could mean patients will have a therapy specific to their disease, rather than burdensome symptom-by-symptom treatment.
